ArticleBlood cancer journal2017
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
R T Swords et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
30 papers cite it
this papercites it